- Home
- GERN
GERN
Geron Corporation
as 07-26-2024 4:00pm EST
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 2.7B | IPO Year: | 1996 |
| Target Price: | $6.93 | AVG Volume (30 days): | 9.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.64 - $5.34 | Next Earning Date: | 08-08-2024 |
| Revenue: | $520,000 | Revenue Growth: | 5.26% |
| Revenue Growth (this year): | 22289.87% | Revenue Growth (next year): | 386.88% |
Latest Geron Corporation News
GERN Breaking Stock News: Dive into GERN Ticker-Specific Updates for Smart Investing
MT Newswires
10 hours ago
Geron's Rytelo Gets NCCN Recommendation for Treatment of Symptomatic Anemia in Myelodysplastic Syndromes
Business Wire
13 hours ago
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
BioPharma Dive
3 days ago
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
MT Newswires
3 days ago
Update: Geron Chief Commercial Officer Anil Kapur to Leave at End of August; Shares Drop Premarket
MT Newswires
3 days ago
Geron Chief Commercial Officer Anil Kapur to Leave at the End of August
Business Wire
3 days ago
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
Zacks
3 days ago
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
Business Wire
8 days ago
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
Compare GERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GERN Geron Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.